What is Sulfanilamide
Sulfanilamide is a topical antiinfective agent for vaginal use. It is only for the treatment of vulvovaginal candidiasis due to Candida albicans. Vaginal formulations of sulfanilamide are specially compounded to a pH approximately equal to that of the normal vagina (about 4.3).
This helps to encourage growth of the normally occurring Doderlein’s bacilli. In earlier years, the efficacy of intravaginal sulfonamides for treating vulvovaginal candidiasis was in question.
The manufacturer product literature now reports 3 studies that show sulfanilamide is significantly more effective than placebo (see AVC(R) product literature). Sulfanilamde was approved by the FDA in 1939.
- Candida albicans
- vulvovaginal candidiasis
- vaginal irritation
The most common reactions to intravaginal administration of sulfanilamide are local sensitivity reactions (0.2%). These reactions include increased vaginal irritation or a burning sensation.
Because sulfonamides are absorbed from the vaginal mucosa, systemic adverse events are possible. Deaths associated with the administration of oral sulfonamides have occurred due to hypersensitivity reactions, such as agranulocytosis, aplastic anemia, and other blood dyscrasias.
Other rarely reported adverse events associated with oral sulfonamides include goiter, diuresis, and hypoglycemia. If either local or systemic hypersensitivity reactions occur, sulfanilamide treatment should be discontinued.
- glucose-6-phosphate dehydrogenase (G6PD) activity
- carbonic anhydrase inhibitor hypersensitivity
- G6PD deficiency
- hepatic disease
- renal failure
- renal impairment
- sulfonamide hypersensitivity
- sulfonylurea hypersensitivity
- thiazide diuretic hypersensitivity
There are no drug interactions associated with Sulfanilamide products.